SE447961B - Stabil, etomidathaltig infusionsvetska for intravenos administrering - Google Patents
Stabil, etomidathaltig infusionsvetska for intravenos administreringInfo
- Publication number
- SE447961B SE447961B SE7907621A SE7907621A SE447961B SE 447961 B SE447961 B SE 447961B SE 7907621 A SE7907621 A SE 7907621A SE 7907621 A SE7907621 A SE 7907621A SE 447961 B SE447961 B SE 447961B
- Authority
- SE
- Sweden
- Prior art keywords
- etomidate
- solution
- infusion
- stable
- physiologically acceptable
- Prior art date
Links
- 238000001802 infusion Methods 0.000 title claims description 5
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 claims description 23
- 229960001690 etomidate Drugs 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000003978 infusion fluid Substances 0.000 claims description 13
- 238000001990 intravenous administration Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- NCDXBSVHIGDPOE-RFVHGSKJSA-N ethyl 3-[(1r)-1-phenylethyl]imidazole-4-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NCDXBSVHIGDPOE-RFVHGSKJSA-N 0.000 claims description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- YCUUCSZGTWIJDW-RFVHGSKJSA-N ethyl 3-[(1r)-1-phenylethyl]imidazole-4-carboxylate;sulfuric acid Chemical compound OS(O)(=O)=O.CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 YCUUCSZGTWIJDW-RFVHGSKJSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94223678A | 1978-09-14 | 1978-09-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7907621L SE7907621L (sv) | 1980-03-15 |
| SE447961B true SE447961B (sv) | 1987-01-12 |
Family
ID=25477775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7907621A SE447961B (sv) | 1978-09-14 | 1979-09-13 | Stabil, etomidathaltig infusionsvetska for intravenos administrering |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4289783A (da) |
| JP (1) | JPS5547858A (da) |
| BE (1) | BE878709A (da) |
| CA (1) | CA1140048A (da) |
| CH (1) | CH651752A5 (da) |
| CY (1) | CY1254A (da) |
| DE (1) | DE2937290A1 (da) |
| DK (1) | DK154926C (da) |
| ES (1) | ES484160A1 (da) |
| FR (1) | FR2435945A1 (da) |
| GB (1) | GB2029700B (da) |
| GR (1) | GR64915B (da) |
| HK (1) | HK80984A (da) |
| HU (1) | HU179989B (da) |
| IE (1) | IE48689B1 (da) |
| IT (1) | IT1120537B (da) |
| KE (1) | KE3426A (da) |
| NL (1) | NL7906835A (da) |
| SE (1) | SE447961B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ225045A (en) * | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| WO2008112641A2 (en) * | 2007-03-09 | 2008-09-18 | New York University | Methods and compositions for treating thalamocortical dysrhythmia |
| RU2484764C2 (ru) | 2007-12-20 | 2013-06-20 | Акарикс А/С | Клейкая накладка для мониторинга акустических сигналов |
| RU2540116C2 (ru) | 2008-03-31 | 2015-02-10 | Дзе Дженерал Хоспитал Корпорейшн | Аналоги этомидата с улучшенными фармакокинетическими и фармакодинамическими свойствами |
| WO2011005969A2 (en) | 2009-07-10 | 2011-01-13 | The General Hospital Corporation | Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| CN104168899B (zh) | 2012-01-13 | 2017-04-05 | 通用医疗公司 | 麻醉剂化合物及其相关的使用方法 |
| EP3206683A4 (en) | 2014-10-16 | 2018-06-13 | The Board of Trustees of the Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354173A (en) * | 1964-04-16 | 1967-11-21 | Janssen Pharmaceutica Nv | Imidazole carboxylates |
-
1979
- 1979-07-23 GR GR59677A patent/GR64915B/el unknown
- 1979-07-27 CY CY1254A patent/CY1254A/en unknown
- 1979-07-27 GB GB7926364A patent/GB2029700B/en not_active Expired
- 1979-08-23 IT IT50093/79A patent/IT1120537B/it active
- 1979-09-05 FR FR7922235A patent/FR2435945A1/fr active Granted
- 1979-09-05 CA CA000335043A patent/CA1140048A/en not_active Expired
- 1979-09-11 JP JP11579179A patent/JPS5547858A/ja active Granted
- 1979-09-11 BE BE0/197088A patent/BE878709A/nl not_active IP Right Cessation
- 1979-09-13 IE IE1741/79A patent/IE48689B1/en not_active IP Right Cessation
- 1979-09-13 HU HU79JA855A patent/HU179989B/hu not_active IP Right Cessation
- 1979-09-13 DK DK384379A patent/DK154926C/da not_active IP Right Cessation
- 1979-09-13 NL NL7906835A patent/NL7906835A/nl not_active Application Discontinuation
- 1979-09-13 ES ES484160A patent/ES484160A1/es not_active Expired
- 1979-09-13 SE SE7907621A patent/SE447961B/sv not_active IP Right Cessation
- 1979-09-14 CH CH8358/79A patent/CH651752A5/de not_active IP Right Cessation
- 1979-09-14 DE DE19792937290 patent/DE2937290A1/de not_active Ceased
-
1980
- 1980-01-16 US US06/112,671 patent/US4289783A/en not_active Expired - Lifetime
-
1984
- 1984-07-20 KE KE3426A patent/KE3426A/xx unknown
- 1984-11-25 HK HK809/84A patent/HK80984A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2937290A1 (de) | 1980-04-03 |
| JPS5547858A (en) | 1980-04-05 |
| GB2029700A (en) | 1980-03-26 |
| IT7950093A0 (it) | 1979-08-23 |
| SE7907621L (sv) | 1980-03-15 |
| HU179989B (en) | 1983-01-28 |
| JPH0214058B2 (da) | 1990-04-06 |
| ES484160A1 (es) | 1980-10-01 |
| GB2029700B (en) | 1983-03-30 |
| GR64915B (en) | 1980-06-09 |
| DK384379A (da) | 1980-03-15 |
| HK80984A (en) | 1984-11-25 |
| FR2435945A1 (fr) | 1980-04-11 |
| NL7906835A (nl) | 1980-03-18 |
| IT1120537B (it) | 1986-03-26 |
| CH651752A5 (de) | 1985-10-15 |
| US4289783A (en) | 1981-09-15 |
| IE48689B1 (en) | 1985-04-17 |
| CA1140048A (en) | 1983-01-25 |
| FR2435945B1 (da) | 1983-02-25 |
| DK154926C (da) | 1989-05-29 |
| BE878709A (nl) | 1980-03-11 |
| CY1254A (en) | 1984-08-31 |
| DK154926B (da) | 1989-01-09 |
| KE3426A (en) | 1984-08-10 |
| IE791741L (en) | 1980-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Slyke et al. | Relationships between urea excretion, renal blood flow, renal oxygen consumption, and diuresis. The mechanism of urea excretion | |
| RU2028142C1 (ru) | Фармацевтический раствор | |
| KR920003332B1 (ko) | 에토포시드(Etoposide)제제의 제조방법 | |
| IE80548B1 (en) | New compositions containing taxane derivatives | |
| CA1093966A (en) | Instillation composition | |
| DE60215129T3 (de) | Esmolol-enthaltende zubereitungen | |
| US4289783A (en) | Etomidate-containing compositions | |
| CN108158991A (zh) | 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂 | |
| BR112013005763A2 (pt) | injeção de 5 - androstano-3b, 5, 6b-triol e método para preparação de injeção | |
| Dixon et al. | Apparent Lack of Interaction Between Dimethyl Sulfoxide (DMSO) and a Variety of Drugs. | |
| EP2421522A1 (de) | Paracetamol zur parenteralen verabreichung | |
| US4696814A (en) | Parenteral phenytoin compositions | |
| DE112016001715T5 (de) | Stabile flüssige pharmazeutische Zusammensetzungen von Bortezomib | |
| JPH0338519A (ja) | ビタミンａ類含有点眼剤 | |
| FI90824C (fi) | Menetelmä kylmäkuivattujen farmaseuttisten fenyylikinoliinikarboksyylihappokoostumusten valmistamiseksi | |
| JP3917820B2 (ja) | オザグレルナトリウム含有注射液およびその安定化方法 | |
| JP3781308B2 (ja) | アルギニンアミド類を含有する医薬製剤 | |
| KR830000526B1 (ko) | 에토 미데이트를 함유한 주사제의 제조방법 | |
| JP2946015B2 (ja) | 安定な抗ウィルス点滴用注射剤 | |
| RU2313346C2 (ru) | Фармацевтическая композиция | |
| EP0920320A2 (fr) | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol | |
| Li et al. | Acute toxicity of monacetin, diacetin and triacetin | |
| US4088759A (en) | Injectable pharmaceutical solutions | |
| EP0055593A2 (en) | Compositions comprising E-prostaglandins | |
| Rosenthal et al. | Paradoxical shortening of the coagulation time of the blood after intravenous administration of sodium citrate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7907621-2 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 7907621-2 Format of ref document f/p: F |